| 1 | Busulfan, cyclophosphamide, antithymocyte globulin | Busulfan | 3件: D00248D00248, D00287D00287, D07760D07760 💬 | - | - | 0192件: 19, 20 💬 | 
| 2 | Busulfan, cyclophosphamide, atg | Busulfan | 3件: D00248D00248, D00287D00287, D07760D07760 💬 | - | - | 0191件: 19 💬 | 
| 3 | Busulfan, cyclophosphamide, atg, gcsf | Busulfan | 3件: D00248D00248, D00287D00287, D07760D07760 💬 | - | - | 0652件: 65, 284 💬 | 
| 4 | Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen) | Antithymocyte immunoglobulin (rabbit) | 5件: D00248D00248, D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 3261件: 326 💬 | 
| 5 | Busulfan, fludarabine, & cyclophosphamide with immunosuppression with atg and cyclosporine. | Busulfan | 6件: D00184D00184, D00248D00248, D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | PPP3CA6件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2, RRM1 💬 | Alzheimer disease37件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Glutathione metabolism, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Pyrimidine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 0602件: 60, 285 💬 | 
| 6 | Campath, fludarabine, cyclophosphamide | Cyclophosphamide | 4件: D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 0652件: 65, 284 💬 | 
| 7 | Cyclophosphamid | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0661件: 66 💬 | 
| 8 | Cyclophosphamide | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 01144件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 💬 | 
| 9 | Cyclophosphamide (cy) | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0601件: 60 💬 | 
| 10 | Cyclophosphamide (cy) (plan 1) | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0602件: 60, 285 💬 | 
| 11 | Cyclophosphamide (cy) (plan 2) | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0602件: 60, 285 💬 | 
| 12 | Cyclophosphamide (cytoxan) | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0651件: 65 💬 | 
| 13 | Cyclophosphamide (drug) | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0131件: 13 💬 | 
| 14 | Cyclophosphamide + pred | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 2831件: 283 💬 | 
| 15 | Cyclophosphamide 100mg | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0601件: 60 💬 | 
| 16 | Cyclophosphamide 150mg | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0601件: 60 💬 | 
| 17 | Cyclophosphamide 30 | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0653件: 65, 285, 326 💬 | 
| 18 | Cyclophosphamide 40 | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0653件: 65, 285, 326 💬 | 
| 19 | Cyclophosphamide 50mg | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0601件: 60 💬 | 
| 20 | Cyclophosphamide 50mg oral tablet | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 1621件: 162 💬 | 
| 21 | Cyclophosphamide and atg | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0131件: 13 💬 | 
| 22 | Cyclophosphamide and fludarabine | Cyclophosphamide | 4件: D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 0131件: 13 💬 | 
| 23 | Cyclophosphamide and steroids | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 2221件: 222 💬 | 
| 24 | Cyclophosphamide dose level 1 | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0652件: 65, 284 💬 | 
| 25 | Cyclophosphamide dose level 2 | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0652件: 65, 284 💬 | 
| 26 | Cyclophosphamide dose level 3 | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0652件: 65, 284 💬 | 
| 27 | Cyclophosphamide dose level 4 | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0652件: 65, 284 💬 | 
| 28 | Cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids | Azathioprine | 6件: D00142D00142, D00238D00238, D00287D00287, D02115D02115, D03033D03033, D07760D07760 💬 | DHFR2件: DHFR, DHFR2 💬 | Antifolate resistance5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate | 0441件: 44 💬 | 
| 29 | Cyclophosphamide injection 1g | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0503件: 50, 51, 52 💬 | 
| 30 | Cyclophosphamide monohydrate | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0134件: 13, 60, 96, 256 💬 | 
| 31 | Cyclophosphamide post transplant | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0651件: 65 💬 | 
| 32 | Cyclophosphamide(ctx) | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 2241件: 224 💬 | 
| 33 | Cyclophosphamide, azathioprine,prednisone,methylprednisolone | Azathioprine | 11件: D00238D00238, D00287D00287, D00407D00407, D00473D00473, D00751D00751, D00979D00979, D03033D03033, D05000D05000, D05001D05001, D05002D05002, D07760D07760 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0423件: 42, 43, 45 💬 | 
| 34 | Cyclophosphamide, bortezomib, and dexamethasone (cybord) | Bortezomib | 12件: D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150, D07760D07760 💬 | NR3C12件: NR3C1, PSMB5 💬 | Alzheimer disease9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia | 0281件: 28 💬 | 
| 35 | Cyclophosphamide, bortezomib, dexamethasone | Bortezomib | 12件: D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150, D07760D07760 💬 | NR3C12件: NR3C1, PSMB5 💬 | Alzheimer disease9件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia | 0281件: 28 💬 | 
| 36 | Cyclophosphamide, bortezomib, dexamethasone plus daratumumab | Bortezomib | 13件: D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D03150D03150, D07760D07760, D10777D10777 💬 | CD383件: CD38, NR3C1, PSMB5 💬 | Alzheimer disease16件: Alzheimer disease, Amyotrophic lateral sclerosis, Calcium signaling pathway, Hematopoietic cell lineage, Huntington disease, Metabolic pathways, Neuroactive ligand-receptor interaction, Nicotinate and nicotinamide metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Salivary secretion, Spinocerebellar ataxia | 0281件: 28 💬 | 
| 37 | Cyclophosphamide, fludarabine | Cyclophosphamide | 4件: D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 2851件: 285 💬 | 
| 38 | Cyclophosphamide, fludarabine , thymoglobulin | Antithymocyte immunoglobulin (rabbit) | 4件: D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 0601件: 60 💬 | 
| 39 | Cyclophosphamide, fludarabine, rabbit atg | Antithymocyte immunoglobulin (rabbit) | 4件: D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 0601件: 60 💬 | 
| 40 | Cyclophosphamide, fludarabine, thymoglobulin | Antithymocyte immunoglobulin (rabbit) | 4件: D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 0601件: 60 💬 | 
| 41 | Cyclophosphamide,campath ih and tbi | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0601件: 60 💬 | 
| 42 | Cyclophosphamide,cyclosporine a | Cyclophosphamide | 3件: D00184D00184, D00287D00287, D07760D07760 💬 | PPP3CA5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | Alzheimer disease32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway | 0601件: 60 💬 | 
| 43 | Cyclophosphamide-prednisone-azathioprine | Azathioprine | 5件: D00238D00238, D00287D00287, D00473D00473, D03033D03033, D07760D07760 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0491件: 49 💬 | 
| 44 | Cyclophosphamide/glatiramer acetate | Acetate | 3件: D00287D00287, D04318D04318, D07760D07760 💬 | HLA-A20件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | Allograft rejection32件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis | 0131件: 13 💬 | 
| 45 | Cyclophosphamidum | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0441件: 44 💬 | 
| 46 | Cyclophosphamidum 500 mg | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0441件: 44 💬 | 
| 47 | Fludarabine, cyclophosphamide | Cyclophosphamide | 4件: D00287D00287, D01907D01907, D07760D07760, D07966D07966 💬 | RRM11件: RRM1 💬 | Drug metabolism - other enzymes5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism | 0601件: 60 💬 | 
| 48 | Haploidentical hsct using tbi free regimen, ''atg'' with ''post transplant cyclophosphamide'' | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0601件: 60 💬 | 
| 49 | High-dose cyclophosphamide | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0961件: 96 💬 | 
| 50 | Iv cyclophosphamide | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0511件: 51 💬 | 
| 51 | Lenalidomide, dexamethasone and cyclophosphamide | Cyclophosphamide | 12件: D00287D00287, D00292D00292, D00975D00975, D01510D01510, D01615D01615, D01632D01632, D01948D01948, D02174D02174, D02591D02591, D02592D02592, D04687D04687, D07760D07760 💬 | NR3C12件: NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications66件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 0281件: 28 💬 | 
| 52 | Prednisone and cyclophosphamide | Cyclophosphamide | 3件: D00287D00287, D00473D00473, D07760D07760 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0661件: 66 💬 | 
| 53 | Prednisone plus cyclophosphamide | Cyclophosphamide | 3件: D00287D00287, D00473D00473, D07760D07760 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0661件: 66 💬 | 
| 54 | Prednisone, cyclophosphamide | Cyclophosphamide | 3件: D00287D00287, D00473D00473, D07760D07760 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0401件: 40 💬 | 
| 55 | Prednisone, methylprednisolone,cyclophosphamides | Methylprednisolone | 7件: D00407D00407, D00473D00473, D00751D00751, D00979D00979, D05000D05000, D05001D05001, D05002D05002 💬 | NR3C11件: NR3C1 💬 | Neuroactive ligand-receptor interaction1件: Neuroactive ligand-receptor interaction | 0423件: 42, 43, 45 💬 | 
| 56 | Procedure: cyclophosphamide | Cyclophosphamide | 2件: D00287D00287, D07760D07760 💬 | - | - | 0651件: 65 💬 | 
| 57 | Rituximab and cyclophosphamide iv | Cyclophosphamide | 3件: D00287D00287, D02994D02994, D07760D07760 💬 | MS4A11件: MS4A1 💬 | Hematopoietic cell lineage1件: Hematopoietic cell lineage | 0351件: 35 💬 | 
| 58 | Thalidomide, cyclophosphamide and prednisone | Cyclophosphamide | 4件: D00287D00287, D00473D00473, D00754D00754, D07760D07760 💬 | NR3C12件: NR3C1, TNF 💬 | AGE-RAGE signaling pathway in diabetic complications66件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Neuroactive ligand-receptor interaction, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway | 3311件: 331 💬 |